可溶性纤溶酶原激活剂受体在急性骨髓系白血病中的预后意义

The prognostic significance of soluble urokinase plasminogen activator receptor in acute myeloid leukemia

目的探讨血清可溶性尿激酶纤溶酶原激活物受体(su PAR)水平对急性骨髓系白血病(AML)患者预后的影响。方法选取初次就诊于潍坊医学院附属医院的AML患者30例,并于门诊随机抽取29名健康受试者作为对照组。通过酶联免疫吸附测定法(ELISA)检测所有研究对象血清su PAR水平。结果 AML患者血清su PAR水平明显高于健康受试者(P<0.001)。在su PAR水平和白细胞计数之间确定正相关(P<0.01)。达到完全缓解的患者血清su PAR水平低于未达到完全缓解的患者(P<0.001)。血清su PAR水平低于6.71μg/L的患者的中位总生存期比血清su PAR水平高于6.71μg/L(P=0.02)的患者中位数总体生存期更长。多因素Cox回归分析显示,在AML中,su PAR具有独立的预后价值(P<0.05)。结论血清su PAR水平可作为AML预后评估指标。

Objective The levels of soluble urokinase plasminogen activator receptor（suPAR） have been demonstrated to correlate with prognosis in various cancers. This study was intended to investigate serum suPAR levels and their effect on prognosis in patients with acute myeloid leukemia（AML）. Methods Thirty newly diagnosed patients in the affiliated hospital of weifang medical university with AML and 29 healthy individuals were enrolled. Serum suPAR levels were analyzed by enzyme-linked immunosorbent assay. Results Serum suPAR levels were significantly higher in patients with AML than in healthy individuals（P 〈0.01）. Positive correlation was determined between suPAR levels and white blood cell counts（P 〈0.01）. Serum suPAR levels were lower in patients who achieved complete response than in patients not achieving complete response（P 〈0. 001）. The median overall survival was longer in patients with serum suPAR levels below 6.71μg/L than in those with serum suPAR levels above 6. 71μg/L（P = 0. 02）. Multivariate Cox regression analysis showed that suPAR had independent prognostic value（P〈 0. 05） in AML. Conclusion Serum suPAR levels can be used as a prognostic marker in AML.